100 related articles for article (PubMed ID: 8986135)
21. Gene-specific damage produced by cisplatin, ormaplatin and UV light in human cells as assayed by the polymerase chain reaction.
Oshita F; Eastman A
Oncol Res; 1993; 5(3):111-8. PubMed ID: 8260747
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
23. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.
Perego P; Caserini C; Gatti L; Carenini N; Romanelli S; Supino R; Colangelo D; Viano I; Leone R; Spinelli S; Pezzoni G; Manzotti C; Farrell N; Zunino F
Mol Pharmacol; 1999 Mar; 55(3):528-34. PubMed ID: 10051537
[TBL] [Abstract][Full Text] [Related]
24. Complementation analysis of testis tumor cells.
Wang X; Hafezparast M; Masters JR
Cancer Genet Cytogenet; 1997 Oct; 98(1):56-62. PubMed ID: 9309119
[TBL] [Abstract][Full Text] [Related]
25. Strand-specific measurement of cisplatin-induced DNA damage and repair using quantitative PCR.
Bingham JP; Hartley JA; Souhami RL; Grimaldi KA
Nucleic Acids Res; 1996 Mar; 24(5):987-9. PubMed ID: 8600473
[No Abstract] [Full Text] [Related]
26. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
27. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
28. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
29. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.
Zisowsky J; Koegel S; Leyers S; Devarakonda K; Kassack MU; Osmak M; Jaehde U
Biochem Pharmacol; 2007 Jan; 73(2):298-307. PubMed ID: 17097621
[TBL] [Abstract][Full Text] [Related]
30. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells.
Qiu YY; Mirkin BL; Dwivedi RS
Cancer Detect Prev; 2005; 29(5):456-63. PubMed ID: 16185816
[TBL] [Abstract][Full Text] [Related]
32. Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin.
Dempke W; Voigt W; Grothey A; Schmoll HJ
Anticancer Drugs; 1999 Jul; 10(6):545-9. PubMed ID: 10885902
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines.
Wilson C; Yang J; Strefford JC; Summersgill B; Young BD; Shipley J; Oliver T; Lu YJ
Genes Chromosomes Cancer; 2005 Jun; 43(2):211-6. PubMed ID: 15761863
[TBL] [Abstract][Full Text] [Related]
34. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
35. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
36. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles.
Duale N; Lindeman B; Komada M; Olsen AK; Andreassen A; Soderlund EJ; Brunborg G
Mol Cancer; 2007 Aug; 6():53. PubMed ID: 17711579
[TBL] [Abstract][Full Text] [Related]
37. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.
Lai KK; Chan KT; Choi MY; Wang HK; Fung EY; Lam HY; Tan W; Tung LN; Tong DK; Sun RW; Lee NP; Law S
Tumour Biol; 2016 Feb; 37(2):2127-36. PubMed ID: 26346170
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.
Lee KB; Parker RJ; Bohr V; Cornelison T; Reed E
Carcinogenesis; 1993 Oct; 14(10):2177-80. PubMed ID: 8222071
[TBL] [Abstract][Full Text] [Related]
40. The Cockayne syndrome group B DNA repair protein as an anti-cancer target.
Lu Y; Mani S; Kandimalla ER; Yu D; Agrawal S; States JC; Bregman DB
Int J Oncol; 2001 Dec; 19(6):1089-97. PubMed ID: 11713576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
